Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 49,100 shares, a growth of 18.3% from the May 30th total of 41,500 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 50,100 shares, the short-interest ratio is presently 1.0 days.
Separately, HC Wainwright reiterated a “buy” rating on shares of Oramed Pharmaceuticals in a research note on Wednesday, June 19th.
ORMP remained flat at $$3.30 during trading on Friday. 12,515 shares of the company’s stock were exchanged, compared to its average volume of 26,540. Oramed Pharmaceuticals has a 1 year low of $2.78 and a 1 year high of $6.02. The company has a fifty day moving average of $3.32. The stock has a market cap of $57.36 million, a P/E ratio of -3.84 and a beta of 1.37.
A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. BlackRock Inc. grew its position in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,343 shares of the biotechnology company’s stock after purchasing an additional 40,114 shares during the period. BlackRock Inc. owned about 0.40% of Oramed Pharmaceuticals worth $208,000 as of its most recent filing with the SEC. 6.18% of the stock is owned by hedge funds and other institutional investors.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Featured Article: What is the Quick Ratio?
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.